Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced today the topline results from the phase 1 clinical trial for its opioid withdrawal treatment drug candidate. The drug is said to have shown favorable safety and tolerability among the trial’s subjects.
“As there is a major unmet need to address the ongoing and ever-growing opioid crisis, we are very pleased with the results from our Phase 1 trial, which underscore the potential clinical utility of MM-110 to safely mitigate symptoms of opioid withdrawal,” said Chief Medical Officer Dr. Daniel Karlin.
The phase 1 trial was designed to assess the safety, tolerability, pharmacokinetics, and neurocognitive effects of MM-110 in 108 healthy subjects. The results showed that the drug administration was well-tolerated up to 500mg per day in the single ascending dose and 60 mg per day for seven days in the multiple-ascending dose.
Sponsored · Altamira Gold Corp.
No serious adverse effects were also observed in the trial.
According to the biotech firm, MM-110 is an α3β4 nicotinic cholinergic receptor antagonist and non-hallucinogenic proprietary congener of ibogaine.
The results have been guiding the firm’s upcoming phase 2a trial.
Mind Medicine Inc. last traded at $0.94 on the NEO.
Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
